SeqCure Immunology has developed several technologies to support its generation of T cells that are both potent and specific.
SpecificiT™
Enables generation of highly pure antigen-specific T cells.
TTT™
Method to enhance the growth of SeqCure T cell products.
BoosT™ and ConTrol™
Methods to control the differentiation and function of SeqCure T cell products.
MigraT™
Methods to enhance the migration of SeqCure T cell products.
Vidar Wendel-Hansen, PhD Chief Executive Officer Vidar has a PhD in tumor biology from the Karolinska Institute. After a few years in clinical practice, he embarked on a career within life science industry. He has extensive experience from management positions within pharmaceutical companies such as Novartis and Gilead Sciences, as well as from smaller biotech startups. Vidar has also worked as a clinical assessor at the Swedish Medical Products Agency.
Robert Wallin, PhD Chief Scientific Officer
Ludvig Linton, PhD Chief Operating Officer
SpecificiT generates highly pure tumor-reactive T cells.
Melanoma-specific T cells generated with SpecificiT are potent killers of melanoma cells.
.png){kind=spacer}
